@article{mbs:/content/journal/jmm/10.1099/jmm.0.058388-0, author = "Muldrew, Kenneth L. and Lovett, Jennie L.", title = "An in-house assay for BK polyomavirus quantification using the Abbott m2000 RealTime system", journal= "Journal of Medical Microbiology", year = "2013", volume = "62", number = "11", pages = "1714-1720", doi = "https://doi.org/10.1099/jmm.0.058388-0", url = "https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.058388-0", publisher = "Microbiology Society", issn = "1473-5644", type = "Journal Article", abstract = "BK polyomavirus (BKPyV) quantification is useful for monitoring renal transplant patient response to therapy. The Abbott m2000 RealTime System employed by some clinical laboratories to perform US Food and Drug Administration-approved assays can also be used to develop in-house assays such as the one presented here. This study aimed to validate an in-house quantitative real-time PCR assay targeting the BKPyV major capsid VP1 gene for assessment of viral load using the Abbott m2000 RealTime System. BKPyV load was measured in 95 urine and plasma samples previously tested for BKPyV by one of three laboratories (46 BKPyV-positive samples consisting of 35 plasma and 11 urine samples; 49 samples negative for BKPyV consisting of 47 plasma and two urine samples). Two additional plasma specimens from the College of American Pathologists proficiency testing survey were also analysed. Precision studies were performed by diluting a high-viral-titre patient sample into BKPyV-negative pooled plasma to create high-positive (6.16 log10 copies ml−1) and low-positive (3.16 log10 copies ml−1) samples. For precision studies of inter-assay variability, a high-positive (7.0 log10 copies ml−1) and a low-positive (3.0 log10 copies ml−1) sample were measured in 20 separate runs. The assay’s limit of quantification and limit of detection were 2.70 and 2.25 log10 copies ml−1, respectively. The assay was linear from 2.70 to 9.26 log10 copies ml−1. Of the 48 known positives, 43 were detected as positive, with three reported by the reference laboratory as values lower than the limit of detection. Two known positives at 3.27 and 3.80 log10 copies ml−1 tested negative by the m2000 BKPyV assay. Of the 49 known negative samples, 48 were negative by the m2000 BKPyV load assay, with one sample confirmed positive by a reference laboratory. Qualitative analysis prior to discrepancy testing demonstrated a sensitivity of 89.58 % and a specificity of 97.96 %. Precision studies demonstrated inter-assay coefficients of variation of 0.63 % (high positive) and 4.38 % (low positive). Genotyping was performed on 22 patient samples, of which 21 (95.45 %) were type I and one (4.55 %) was type II. In conclusion, the m2000 BKPyV viral load assay sensitivity, specificity, linear range, precision and cost effectiveness make it an attractive methodology for clinical laboratories using the Abbott m2000 RealTime System.", }